Comparative Overview of MK-677 and LGD-4033
Samuel Sarmiento MD, MPH, MBA
MK-677 and LGD-4033
Both MK-677 and LGD-4033 have been studied for their potential to support musculoskeletal health, particularly in the context of age-related frailty and chronic illness. While they differ mechanistically, both agents have demonstrated effects on body composition and energy regulation.
Structural Characteristics
MK-677 (Ibutamoren)
Formula: C27H36N4O5S
Molecular Mass: 528.7 g/mol
CAS Registry: 159634-47-6
Other Identifiers: Oratrope, L-163,191
LGD-4033 (Ligandrol)
Formula: C14H12F6N2O
Molecular Mass: 338.25 g/mol
CAS Registry: 1165910-22-4
Other Identifiers: VK-5211
Mechanistic Pathways
LGD-4033 This compound is a selective androgen receptor modulator (SARM). It interacts directly with androgen receptors to stimulate anabolic processes, originally investigated for potential use in conditions such as benign prostatic hyperplasia and prostate carcinoma. Early-phase trials suggest it is generally well tolerated, with dose-dependent suppression of testosterone, sex hormone-binding globulin, HDL cholesterol, and triglycerides. Even at modest doses, it enhances lean mass through skeletal muscle growth.
MK-677 Unlike SARMs, MK-677 acts as a growth hormone secretagogue. It mimics ghrelin activity by binding to the GHS-R receptor, thereby elevating growth hormone and IGF-1 secretion. Clinical investigations indicate daily oral use results in an average weight increase of ~2 kg over short intervals, largely from increases in muscle and bone mass without proportional fat accumulation. Appetite stimulation occurs initially but normalizes with continued use. Importantly, MK-677 does not suppress endogenous testosterone, distinguishing it from SARMs in terms of cycle requirements.
Role in Muscle Preservation
SARMs such as LGD-4033 have been of interest in preventing muscle catabolism associated with chronic disease, cancer, and cachexia. Loss of lean mass significantly impacts morbidity, mortality, and patient quality of life. Clinical findings indicate that maintaining muscle mass improves both treatment tolerance and functional capacity.
MK-677 has also demonstrated capacity to support lean tissue accrual. Notably, concurrent use of MK-677 and LGD-4033 may synergistically enhance muscle mass and strength, potentially through modulation of intramuscular androgen receptor dynamics.
Cardiovascular Implications
The cardiovascular effects of SARMs remain uncertain. While they may promote myocardial muscle support, their reduction of HDL cholesterol raises questions about long-term cardiovascular risk.
In contrast, MK-677 appears favorable for cardiovascular health. By elevating growth hormone and IGF-1, it contributes to nitric oxide synthesis, reduces blood pressure, and enhances vascular repair through mobilization of endothelial progenitor cells. Preservation of these cells is associated with reduced risk of atherosclerosis and hypertension. The combined impact of MK-677 and LGD-4033 on cardiac outcomes remains an open area for investigation.
Neurological Considerations
IGF-1 plays a critical role in the clearance of amyloid beta from the central nervous system. Declining IGF-1 with age is thought to contribute to the development of Alzheimer’s disease. MK-677, through sustained elevation of IGF-1, has been investigated as a candidate for neuroprotection. Preclinical models demonstrate reductions in amyloid deposition, neuronal loss, and synaptic decline when treatment is initiated early, highlighting potential disease-modifying properties.
Conclusion
LGD-4033 is among the more promising SARMs, though clinical evidence remains limited. Early findings suggest it supports lean tissue preservation and may influence cardiovascular and neurological health, though long-term risks require clarification.
MK-677, in contrast, has broader clinical data supporting its effects on muscle, bone, vascular health, and neuroprotection. Emerging evidence suggests that combined administration of MK-677 with SARMs like LGD-4033 may yield complementary benefits while mitigating certain adverse effects. Optimal dosing strategies, treatment cycles, and long-term safety remain key areas for further research.
REFERENCES
Basaria, S., Collins, L., Dillon, E. L., Orwoll, K., Storer, T. W., Miciek, R., Ulloor, J., Zhang, A., Eder, R., Zientek, H., Gordon, G., Kazmi, S., Sheffield-Moore, M., & Bhasin, S. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. The journals of gerontology. Series A, Biological sciences and medical sciences, 68(1), 87–95. https://doi.org/10.1093/gerona/gls078
Jeong, Y. O., Shin, S. J., Park, J. Y., Ku, B. K., Song, J. S., Kim, J. J., Jeon, S. G., Lee, S. M., & Moon, M. (2018). MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer’s Disease. International journal of molecular sciences, 19(6), 1800. https://doi.org/10.3390/ijms19061800
Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Jr, Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of internal medicine, 149(9), 601–611. https://doi.org/10.7326/0003-4819-149-9-200811040-00003
Thum, T., Hoeber, S., Froese, S., Klink, I., Stichtenoth, D. O., Galuppo, P., Jakob, M., Tsikas, D., Anker, S. D., Poole-Wilson, P. A., Borlak, J., Ertl, G., & Bauersachs, J. (2007). Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circulation research, 100(3), 434–443. https://doi.org/10.1161/01.RES.0000257912.78915.af